TYK2 Inhibition Promising in Psoriatic Arthritis

Ella Castle

The oral tyrosine kinase 2 inhibitor deucravacitinib was effective for the treatment of active psoriatic arthritis in a phase II placebo-controlled trial. At week 16, only 31.8% of patients who had been randomized to receive placebo met the 20% response criteria of the American College of Rheumatology (ACR20), compared with […]

Subscribe US Now

situs judi bola Daftar sekarang dengan cara klik link login slot via dana 24 jam terpercaya, join sekarang slot gacor online dengan pilihan platform game slot pragmatic play paling favorit tahun 2023.